ILLUMINA, INC.

Key metrics

Financial performance

Over the last 8 fiscal years ILLUMINA, INC.'s revenue grew from $2.40B to $4.34B, a compound annual growth rate of 7.7%. Net profit margin expanded from 19.3% to 19.6% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (3,713 filings)

Recent press releases

• David P King Elected To Illuminas Board Of Directors2026-05-21

  Illumina, Inc. - David P. King elected to Illumina's Board of Directors

• Illumina, Inc. - Illumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact2026-05-19

  Illumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact

• Illumina, Inc. - Illumina Reports Financial Results for First Quarter of Fiscal Year 20262026-04-30

  Illumina Reports Financial Results for First Quarter of Fiscal Year 2026

• Illumina launches DRAGEN v4.5, unlocking deep biological signals in complex regions and challenging sample types for rare disease, oncology research2026-04-16

  Illumina, Inc. - DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows

• Illumina And The Center For Data Driven Discovery In Biomedicine Bring Genomic Data And Scalable Software To The Fight Against Pediatric Cancer And Rare Disease2026-04-14

  Illumina, Inc. - Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease

Similar companies

The largest companies sharing ILLUMINA, INC.'s SEC industry classification (laboratory analytical instruments).